Clinical trials: Cervical Carcinoma
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Solid Tumor
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
- Trial name
- innovaTV 206 (NCT03913741)
- Testing
- tisotumab vedotin
- Where
- 8 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Genmab
Epidermal Growth Factor, Epidermal Growth Factor Receptor
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any…
- Conditions
- Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell
- Trial name
- NCT07462377
- Testing
- EPI-326
- Where
- 8 sites in United States, South Korea and 1 more
- Volunteers
- 110 people
- Sponsor
- EpiBiologics
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Head and Neck Squamous Cell Carcinoma
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
It's a prospective, open-label, single arm, nonrandomized study of PEP503 in head and neck squamous cell carcinoma (HNSCC) patients.
- Trial name
- NCT02901483
- Testing
- PEP503, Cisplatin, Radiotherapy
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- PharmaEngine
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with…
- Trial name
- NCT00454779
- Testing
- Cisplatin, Panitumumab, Docetaxel
- Where
- 114 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Amgen
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- NCT04697446
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 279 people
- Sponsor
- Blueprint Medicines Corporation
Head and Neck Squamous Cell Carcinoma
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT06006169
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic).
- Trial name
- NCT04428151
- Testing
- Lenvatinib, Pembrolizumab, Docetaxel
- Where
- 120 sites in United States, Australia and 13 more
- Volunteers
- 408 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Squamous Cell of Head and Neck
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
This is a prospective, observational, non-interventional, multicenter, post-marketing surveillance study to mainly collect safety information from subjects with locally advanced and recurrent/metastatic Squamous Cell Carcinoma of…
- Trial name
- NCT01080066
- Testing
- No Intervention
- Where
- Taiwan
- Volunteers
- 215 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
The purpose of this study is to compare the pharmacokinetic, safety, immunogenicity and efficacy of CMAB819 and Nivolumab in subjects with recurrent or metastatic head and neck squamous cell carcinoma., after failure of prior…
- Trial name
- NCT04659369
- Testing
- CMAB819, Nivolumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05182866
- Testing
- ASP-1929 Photoimmunotherapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rakuten Medical, Inc.
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Solid Tumors
A Study of E7130 in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
- Trial name
- NCT03444701
- Testing
- E7130
- Where
- 9 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eisai Co., Ltd.
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.